MX2018013372A - Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos. - Google Patents

Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos.

Info

Publication number
MX2018013372A
MX2018013372A MX2018013372A MX2018013372A MX2018013372A MX 2018013372 A MX2018013372 A MX 2018013372A MX 2018013372 A MX2018013372 A MX 2018013372A MX 2018013372 A MX2018013372 A MX 2018013372A MX 2018013372 A MX2018013372 A MX 2018013372A
Authority
MX
Mexico
Prior art keywords
inhibitory concentration
evaluating
minimal inhibitory
broth microdilution
polypeptides
Prior art date
Application number
MX2018013372A
Other languages
English (en)
Inventor
Schuch Raymond
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of MX2018013372A publication Critical patent/MX2018013372A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención proporciona componentes, ensayos y métodos para evaluar la efectividad antibacteriana y determinar la concentración inhibitoria mínima (MIC) de polipéptidos, incluyendo polipéptidos de lisina, que matan bacterias. Se proporcionan componentes y métodos de microdilución en caldo modificados, incluyendo suplementos para permitir la determinación MIC precisa que imita la actividad del polipéptido lisina en matrices humanas que incluyen suero y sangre.
MX2018013372A 2016-05-12 2017-05-12 Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos. MX2018013372A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335129P 2016-05-12 2016-05-12
PCT/US2017/032344 WO2017197227A1 (en) 2016-05-12 2017-05-12 Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides

Publications (1)

Publication Number Publication Date
MX2018013372A true MX2018013372A (es) 2019-05-09

Family

ID=60266856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013372A MX2018013372A (es) 2016-05-12 2017-05-12 Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos.

Country Status (14)

Country Link
US (1) US10851401B2 (es)
EP (1) EP3454888B1 (es)
JP (1) JP6875756B2 (es)
KR (1) KR20190004799A (es)
CN (1) CN109152822B (es)
AU (1) AU2017263563A1 (es)
BR (1) BR112018073205A2 (es)
CA (1) CA3023730A1 (es)
DK (1) DK3454888T3 (es)
IL (1) IL262844B2 (es)
MX (1) MX2018013372A (es)
RU (1) RU2754667C2 (es)
WO (1) WO2017197227A1 (es)
ZA (1) ZA201806685B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102441211B1 (ko) 2014-06-26 2022-09-07 더 락커펠러 유니버시티 아시네토박터 라이신
KR20200124724A (ko) * 2018-02-26 2020-11-03 콘트라펙트 코포레이션 변형된 PlySs2 리신 및 이의 용도
CA3106159A1 (en) 2018-07-11 2020-01-16 SeLux Diagnostics, Inc. Assays and reagents for antimicrobial susceptibility testing
KR20210141667A (ko) * 2019-03-22 2021-11-23 콘트라펙트 코포레이션 감염성 심내막염의 치료 방법
CN114025783A (zh) * 2019-04-11 2022-02-08 康特拉费克特公司 治疗和预防骨和关节感染的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002781A1 (en) 1986-10-08 1988-04-21 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
EP1162994A4 (en) 1999-02-25 2004-12-29 New Horizons Diagnostics Inc COMPOSITION FOR THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF STREPTOCOCCAL INFECTIONS
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
JP4381531B2 (ja) * 1999-12-08 2009-12-09 塩野義製薬株式会社 グリコペプチド誘導体
CA2486280A1 (en) 2002-05-17 2004-04-01 New Horizons Diagnostics Corporation Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
EP1744779A2 (en) 2004-03-24 2007-01-24 The Rockfeller University Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores
WO2008018854A2 (en) 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
WO2007024628A2 (en) 2005-08-24 2007-03-01 The Rockefeller University Ply-gbs mutant lysins
CA2984933C (en) 2008-07-03 2020-07-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
JP5823733B2 (ja) * 2010-05-25 2015-11-25 株式会社ゲノム創薬研究所 抗生物質産生微生物及びそれが産生した抗生物質
CA2799572C (en) * 2010-05-25 2018-12-11 Genome Pharmaceuticals Institute Co., Ltd. Novel cyclic peptide compound, method for producing same, anti-infective agent, antibiotic-containing fraction, antibiotic, method for producing antibiotic, antibiotic-producing microorganism, and antibiotic produced by same
JP6139509B2 (ja) 2011-04-21 2017-05-31 ザ ロックフェラー ユニバーシティ グラム陽性細菌を検出および処置するためのＳｔｒｅｐｔｏｃｏｃｃｕｓバクテリオファージリシン
US10813983B2 (en) 2012-05-09 2020-10-27 Contrafect Corporation Bacteriophage lysin and antibiotic combinations against gram positive bacteria

Also Published As

Publication number Publication date
AU2017263563A1 (en) 2018-10-18
KR20190004799A (ko) 2019-01-14
US10851401B2 (en) 2020-12-01
EP3454888A4 (en) 2019-12-11
IL262844A (en) 2018-12-31
IL262844B2 (en) 2023-07-01
JP6875756B2 (ja) 2021-05-26
JP2019514439A (ja) 2019-06-06
CA3023730A1 (en) 2017-11-16
EP3454888B1 (en) 2021-02-24
CN109152822A (zh) 2019-01-04
BR112018073205A2 (pt) 2019-02-19
IL262844B1 (en) 2023-03-01
WO2017197227A1 (en) 2017-11-16
EP3454888A1 (en) 2019-03-20
CN109152822B (zh) 2023-12-05
DK3454888T3 (da) 2021-04-26
US20190106724A1 (en) 2019-04-11
RU2018135238A (ru) 2020-06-15
RU2018135238A3 (es) 2020-09-11
RU2754667C2 (ru) 2021-09-06
ZA201806685B (en) 2021-02-24

Similar Documents

Publication Publication Date Title
MX2018013372A (es) Metodo de microdilucion en caldo para evaluar y determinar la concentracion inhibitoria minima de polipeptidos antibacterianos.
MX2022006447A (es) Anticuerpos anti-pd-1 novedosos.
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
MY201450A (en) Substituted inhibitors of menin-mll and methods of use
MX2018011092A (es) Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso.
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
SA518390862B1 (ar) Pd-l1 أجسام مضادة ضد
MX2021005353A (es) Composiciones, metodos y sistemas para el analisis de la corona proteica y usos de los mismos.
EA201890278A1 (ru) Антитела к pd-l1
DOP2017000171A (es) Proteínas de unión a icos.
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201891291A1 (ru) Мультиспецифические антитела
MD3303379T2 (ro) Agenți de legare TIGIT și utilizări ale acestora
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA202092319A1 (ru) Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
SG10201808208PA (en) Agent comprising imidazole dipeptide
EA202191253A1 (ru) Способы количественного определения олигосахаридных препаратов
BR112016030730A8 (pt) composto
WO2019018841A3 (en) COMPOSITIONS AND METHODS FOR IDENTIFICATION OF COMBINATORIAL IMMUNO-ONCOLOGIC THERAPEUTIC AGENTS
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
MX2020000018A (es) Potencializacion de componentes sanguineos de actividad anti-bacteriana de proteina litica y metodos y usos de estos.
BR112022008821A2 (pt) Ligantes de pseudoquinase tyk2
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.